Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Eylea

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Eylea was produced by Bayer.

Novartis expands eyecare partnership with NHS

Novartis expands eyecare partnership with NHS The update is significant for Novartis as the main competitor for Lucentis in wet AMD - Bayer's Eylea (aflibercept) - is recommended as a monthly treatment for three consecutive doses, followed by

Bayer to spin out material science division

Bayer to spin out material science division New pharmaceutical products will lead the commercial drive at the new Bayer; the company expects he anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Stivarga and Xofigo, and the pulmonary

New eye indication for Allergan’s Ozurdex

New eye indication for Allergan’s Ozurdex Bayer's fast-growing eye drug Eylea (aflibercept) has also been recommended by the Committee for Medicinal Products for Human Use (CHMP), although final approval is still pending. ... It is a similar situation in the US where both Eylea and Lucentis are

Allergan will start phase III DARPin trials next year

Allergan will start phase III DARPin trials next year Chief executive David Pyott pointed out that Bayer's Eylea (aflibercept) has made dramatic gains in market share since launch thanks to a more favourable dosing regimen against Lucentis, which requires

Novartis and NHS launch mobile eye unit in UK

Novartis and NHS launch mobile eye unit in UK The drug was the dominant force in wet AMD treatment for some time, although is now facing a challenge from Bayer's Eylea (aflibercept), which was recommended last year. ... Little separates the two drugs in terms of effectiveness, safety and cost,

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics